Annalisa Morgan, MD, discusses the integration of new treatments presented at the 2025 ACTRIMS Forum into her clinical practice, focusing on CAR T-cell therapy and BTK inhibitors. She plans to use CAR T-cell therapy for younger, less disabled patients with relapsing-remitting multiple sclerosis (MS) who have breakthrough disease, though further research is needed to confirm its broader applicability.
Morgan is cautious about using the BTK inhibitor tolebrutinib for active inflammatory disease, as it didn’t meet primary endpoints, but sees potential in patients transitioning to secondary progressive MS, particularly those with higher paramagnetic rim lesions. Lastly, she stresses the need for further studies to standardize extended-interval dosing of ocrelizumab, which shows promise in older patients or those at higher risk for infections.
